Related Experiment Video
Updated: Mar 11, 2026
A Syngeneic Murine Model of Endometriosis using Naturally Cycling Mice
Published on: November 24, 2020
Mig-6 Mouse Model of Endometrial Cancer
Tae Hoon Kim1, Jung-Yoon Yoo1, Jae-Wook Jeong2
1Department of Obstetrics, Gynecology & Reproductive Biology, Michigan State University College of Human Medicine, Grand Rapids, MI, 49503, USA.
Abstract:
Endometrial cancer is a frequently occurring gynecological disorder. Estrogen-dependent endometrioid carcinoma is the most common type of gynecological cancer. One of the major pathologic phenomena of endometrial cancer is the loss of estrogen (E2) and progesterone (P4) control over uterine epithelial cell proliferation. P4 antagonizes the growth-promoting properties of E2 in the uterus. P4 prevents the development of endometrial cancer associated with unopposed E2 by blocking E2 actions. Mitogen inducible gene 6 (Mig-6, Errfi1, RALT, or gene 33) is an immediate early response gene that can be induced by various mitogens and common chronic stress stimuli. Mig-6 has been identified as an important component of P4-mediated inhibition of E2 signaling in the uterus. Decreased expression of MIG-6 is observed in human endometrial carcinomas. Transgenic mice with Mig-6 ablation in the uterus develop endometrial hyperplasia and E2-dependent endometrial cancer. Thus, MIG-6 has a tumor suppressor function in endometrial tumorigenesis. The following discussion summarizes our current knowledge of Mig-6 mouse models and their role in understanding the molecular mechanisms of endometrial tumorigenesis and in the development of therapeutic approaches for endometrial cancer.
Insights
Mitogen inducible gene 6 (Mig-6) acts as a tumor suppressor in endometrial cancer. Loss of Mig-6 leads to estrogen-driven uterine cell overgrowth and cancer development, highlighting its critical role in preventing gynecological disorders.
Area of Science:
- Gynecological Oncology
- Molecular Biology
- Cancer Genetics
Background:
- Endometrial cancer, particularly estrogen-dependent endometrioid carcinoma, is a common gynecological malignancy.
- Loss of estrogen (E2) and progesterone (P4) signaling control over uterine epithelial cells is a key pathological feature.
- Progesterone antagonizes estrogen's growth-promoting effects, preventing unopposed E2-induced endometrial cancer.
Purpose of the Study:
- To investigate the tumor suppressor role of Mitogen inducible gene 6 (Mig-6) in endometrial tumorigenesis.
- To elucidate the molecular mechanisms underlying endometrial cancer development related to Mig-6.
- To explore the utility of Mig-6 mouse models in developing therapeutic strategies for endometrial cancer.
Main Methods:
- Analysis of Mig-6 expression in human endometrial carcinomas.
- Generation and study of transgenic mice with targeted Mig-6 ablation in the uterus.
- Examination of uterine epithelial cell proliferation and tumor development in Mig-6 deficient mice.
Main Results:
- Decreased expression of Mig-6 is a common finding in human endometrial carcinomas.
- Uterine-specific ablation of Mig-6 in mice results in endometrial hyperplasia.
- Mig-6 deficient mice develop estrogen-dependent endometrial cancer, confirming its tumor suppressor function.
Conclusions:
- Mig-6 plays a crucial role in suppressing endometrial tumorigenesis by mediating progesterone's inhibition of estrogen signaling.
- Mig-6 deficiency leads to uncontrolled uterine cell proliferation and cancer development.
- Mig-6 mouse models are valuable tools for understanding endometrial cancer pathogenesis and for therapeutic development.
More Related Videos
08:07Establishment of an Experimental Mouse Model of Endometrioma to Study its Related Infertility
Published on: April 5, 2024
07:44Non-Invasive Ultrasound Assessment of Endometrial Cancer Progression in Pax8-Directed Deletion of the Tumor Suppressors Arid1a and Pten in Mice
Published on: February 17, 2023
